HSPTR has completed its business combination with SL Bio, transforming from a SPAC searching for a target into a subsidiary of a new public company (PubCo) with shares expected to list on Nasdaq.
This represents the successful consummation of the SPAC's primary objective, as evidenced by the removal of language about searching for targets and extension deadlines, replaced with details about the completed merger structure. Shareholders now own shares in PubCo rather than the original SPAC entity, marking a fundamental transformation of their investment.
The financial statements reflect the dramatic impact of the business combination, with net income surging from $143K to $1.8M while operating cash flow deteriorated significantly from -$110K to -$1.0M. The balance sheet shows severe stress with stockholders' equity turning negative (-$1.3M from +$451K), current assets collapsing 96% to just $30K, and liabilities quintupling to $1.3M. These changes suggest the transaction consumed substantial cash and created financial strain, though this may be typical for SPAC combinations during the transition period.
Net income grew 1166.1% — bottom-line growth signals improving overall business health.
Operating cash flow fell 840.4% — earnings quality concerns; investigate working capital changes and non-cash items.
Liabilities grew 400.9% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 400.9% — significant near-term obligations; verify ability to meet short-term debt.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 95.9% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →